BioMedPartners

BioMedPartners

A European private equity and venture capital firm that provides financing to early- and mid-stage healthcare and human life science companies

BioMedPartners is a European private equity and venture capital firm that provides financing to early- and mid-stage healthcare and human life science companies. Founded 2017 in Basel, Basel-Stadt, Switzerland by Gerhard Ries, the company invests in early and late stage ventures. It usually funds grants, Series A, Series B, Series D, and other venture rounds. Its portfolio companies include Aleva Neurotherapeutics, ImmunOs Therapeutics, Inotrem, Curetis, and Alentis Therapeutics. As of January 2020, the company had 19 exits and 68 investments. The company focuses on pharmaceuticals, biotechnology, diagnostics and medical technology.

Timeline

2017

Founded

Funded Companies

Company
Description
Industry
Website
Location
Hookipa Biotech

A biotechnology company developing immuno-oncology therapies and therapeutic vaccines

Curetis is a Holzheim am Forst-based molecular diagnostic firm developing tools for diagnostics of infectious disease.

Tubulis Therapeutics is a Munich-based therapeutics company developing matched protein-drug conjugates.

ImevaX is a Munich-based medical diagnostics company developing specific tests for infectious diseases and founded in 2014 by Markus Gerhard.

7 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Andreas Wallnöfer

General Partner

Karl Deres

Venture Partner

Patrick Burgermeister

Partner

Stefan Fäs

Chief Financial Officer & Partner

Thomas Möller

General Partner

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

ImmunOs Therapeutics

Alentis Therapeutics

Aleva Neurotherapeutics

Amal Therapeutics

Amal Therapeutics

Camel-IDS

Hookipa Pharma

Miracor Medical

TOLREMO therapeutics

Tricares

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.